Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers N > Headlines for Neurocrine Biosciences, Inc. > News item |
Neurocrine upgraded by Thomas Weisel to outperform
Neurocrine Biosciences Inc. was upgraded by Thomas Weisel Partners analyst Ian Somaiya to outperform from peer perform, citing optimism for the company's generic Ambien insomnia drug Indiplon, being developed with Pfizer. San Diego-based Neurocrine has 17 programs in various stages, including a drug to treat endometriosis. The company also has strategic alliances with Almirall Prodesfarma SA; Wyeth; and Eli Lilly & Co. Neurocrine shares Monday roes $1.21, or 2.53%, to $49.12 on volume of 858,504 shares versus the three-month running average of 490,834.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.